Premium
Obesity and the “Obesity Paradox” in Cardiovascular Diseases
Author(s) -
Lavie CJ,
Milani RV,
Ventura HO
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.87
Subject(s) - obesity , overweight , clinical pharmacology , medicine , disease , weight loss , anti obesity , risk factor , obesity paradox , endocrinology , pharmacology
Obesity adversely affects most cardiovascular (CV) risk factors and is strongly associated, probably as an independent risk factor, with most CV diseases. However, substantial evidence points to the existence of an “obesity paradox,” in that overweight and obese patients with established CV diseases typically have a better prognosis than leaner patients with the same CV disease. Despite this paradox, we believe that the “weight” of evidence still supports efforts at purposeful weight loss in both primary and secondary CV prevention. Clinical Pharmacology & Therapeutics (2011) 90 1, 23–25. doi: 10.1038/clpt.2011.87